Polikistik over sendromunda progesterone tedavisinin pulmoner fonksiyonlara etkisi

Abstract

Amaç: Çalışmamızda, polikistik over sendromlu hastaların solunum fonksiyon testlerinin ve progesteron tedavisinin değerlendirilmesi amaçlanmıştır.solunum fonksiyonlarına etkisinin second FEV1 and forced vital capacity FVC values were found increased after the treatment. Conclusion: Although the pulmonary function of PCOS patients were not different from that of the healthy female population, progesterone treatment has been shown to increase FEV1 and FVC parameters. değerleri ile kontrol grubu arasında anlamlı farklılık saptanmazken, tedavi sonrası FEV1 ve FVC değerleri artmış bulundu

Keywords

• Polikistik over sendromu, medroksiprogesteron asetat, solunum fonksiyon testi

Effects of progesterone treatment in polycystic ovary syndrome on pulmonary functions

Abstract

Objective: We aimed to evaluate patients with polycystic ovary syndrome in terms of respiratory function tests and to investigate the relationship between progesterone therapy and pulmonary functions.Methods: Fifty patients, who were diagnosed polycystic ovary syndrome PCOS according to Rotterdam criteria, at gynecology and obstetrics clinic of a research and training hospital included in the study group. Fifty healthy person were included in the control group. Both groups were evaluated with pulmonary function tests PFT at pulmonary medicine clinic of a university hospital. Independent from PFT survey, the patient group was treated with two cycles of medroxyprogesterone acetate between 16 and 25 days of the cycle as the standart follow up and treatment at gynecology and obstetrics clinic. Afterwards they were evaluated with PFT again. Statistical analysis of independent measurements were analyzed by Student’s t-test. Mann-Whitney U, Wilcoxon test was used to analyze the data without normal distribution. P value

Keywords

• Polycystic ovary syndrome, medroxyprogesterone acetate, pulmonary function test

References

1. Graupp M, Wehr E, Schweighofer N, Pieber TR, Obermayer-Pietsch B. Association of genetic variants in the two isoforms of 5alpha-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol, 2011;157:175–179.
2. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol, 2011;7:219–231.
3. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab, 2001; 86:517.
4. Chatterjee B, Suri J, Suri JC, Mittal P, Adhikari T. Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. Sleep Med, 2014;15 (12), 1547–1553.
5. Zierau L, Gade EJ, Lindenberg S, Backer V, Thomsen SF. Coexistence of asthma and polycystic ovary syndrome: A concise review. Respir Med, 2016; 119:155-9.
6. Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab. 2015;100(3):911-9.
7. Boukari R, Marcouiller F, Joseph V. Relative contribution progesterone receptors in respiratory control. Adv Exp Med Biol.,2015;860:261-7. doi: 10.1007/978-3- 319-18440-1_30. and membrane
8. Real FG , Svanes C, Omenaas ER, Ant o JM, Plana E, Janson C, et al. Menstrual irregularity and asthma and lung function. J Allergy Clin Immunol, 120 (2007) 557e564.

9. Anonymous. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 2004;81:19–25.
10. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J, 2005;26:511–522.
11. Ke RW. Endocrine basis for recurrent pregnancy loss. Obstet Gynecol Clin North Am, 2014;41(1):103-12. doi: 10.1016/j.ogc.2013.10.003.
12. Ucok K, Akkaya M, Genc A, Akcer S, Gonul Y, Cosar E, et al. Assessment of pulmonary functions and anthropometric measurements in women with polycystic ovary syndrome. Gynecological endocrinology : Gynecol Endocrinol, 2010;26(11):827-32.
13. Benyon HLC, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. Lancet, 1988;370–372.
14. Carlson CL, Cushman M, Enright PL, Cauley JA, Newman AB. Hormone replacement therapy is associated with higher FEV1 in elderly women. Am J Respir Crit Care Med, 2001;163(2):423-8.
15. Ucok K, Akkaya M, Genc A, Akcer S, Gonul Y, Cosar E, et al. Assessment of pulmonary functions and anthropometric measurements in women with polycystic ovary syndrome. Gynecol Endocrinol, 2010;26(11):827-32.
16. Hall OJ, Limjunyawong N, Vermillion MS, Robinson DP, Wohlgemuth N, Pekosz A, et al. Progesterone- based therapy protects against influenza by promoting lung repair and recovery in females. PLoS Pathog, 2016; 12(9): e1005840. doi:10.1371/ journal.ppat.1005840.
17. Slatkovska L, Jensen D, Davies GA, Wolfe LA. Phasic menstrual cycle effects on the control of breathing in healthy women. Respir Physiol Neurobiol, 2006;154:379–388.
18. Bayliss DA, Millhorn DE. Central neural mechanisms of progesterone action: application to the respiratory system. J Appl Physiol, 1992;73(2):393– 404.
19. Tatsumi K, Mikami M, Kuriyama T, Fukuds Y. Respiratory stimulation by female hormones in awake male rats. J Appl Physiol, 1991;71:37–42.
20. Monks DA, Arciszewska G, Watson NV. Estrogen- inducible progesterone receptors in the rat lumbar spinal cord: regulation by ovarian steroids and fluctuation across the estrous cycle. Horm Behav, 2001;40:490–496.
21. Feldman JL, McCrimmon DR. Neural Control of Breathing. In: Squire LR, Bloom FE, McConnell SK, Roberts JL, Spitzer NC, Zigmond MJ, editors. Fundamental Neuroscience. 2nd ed. San Diego: Elsevier, Academic Press; 2003. pp. 967–990.